Combikit of 1 Tab Fluconazole 150mg + 1 Tab Azithromycin 1gm + 2 Tabs Secnidazole 1gm
VAGIMIST KIT is a uniquely designed single-visit STI treatment kit containing three mechanistically distinct agents that together provide complete empirical coverage for the most common female genital tract infections in a single dispensing.
Fluconazole (150mg, 1 tablet): A triazole antifungal that inhibits lanosterol 14-alpha-demethylase (CYP51), blocking ergosterol synthesis in the fungal cell membrane. A single 150mg dose achieves therapeutic concentrations in vaginal secretions for 72 hours — sufficient for complete eradication of susceptible Candida albicans, the causative organism of vulvovaginal candidiasis.
Azithromycin (1gm, 1 tablet): A macrolide antibiotic that binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis. A single 1gm dose is the WHO-recommended single-dose treatment for uncomplicated genital Chlamydia trachomatis infection and non-gonococcal urethritis/cervicitis. The 1gm dose achieves genital tissue concentrations that persist above the MIC for Chlamydia for 10 days post-single-dose administration.
Secnidazole (1gm × 2 tablets = 2gm total): A second-generation nitroimidazole that generates reactive radical intermediates within anaerobic and protozoal organisms, causing lethal DNA strand breaks. A single 2gm dose of secnidazole is FDA-approved and WHO-recommended for bacterial vaginosis (BV) and trichomoniasis. Secnidazole has a longer half-life (17–29 hours) than metronidazole, enabling a single-dose treatment regimen that provides superior compliance versus multi-day metronidazole courses. It covers Gardnerella vaginalis, Prevotella species (BV organisms), and Trichomonas vaginalis.
VAGIMIST KIT is designed for empirical, single-visit treatment of mixed genital tract infections in women — the most common clinical scenario in gynaecology and STI practice where multiple concurrent infections are frequently present.
Vulvovaginal Candidiasis + Bacterial Vaginosis + STI Empirical Cover: The most common clinical presentation in gynaecology OPDs where vaginal discharge is the presenting complaint. Rather than prescribing three separate medicines across multiple visits (which patients frequently do not complete), VAGIMIST KIT provides a single-visit, single-dispensing complete treatment.
Chlamydial Cervicitis: Azithromycin 1gm single dose is the first-line WHO-recommended treatment for uncomplicated genital chlamydial infection.
Bacterial Vaginosis: Secnidazole 2gm single dose is FDA-approved for BV — superior to 7-day metronidazole in compliance and equivalent in efficacy.
Trichomoniasis: Secnidazole 2gm covers Trichomonas vaginalis — the same single-dose approach as recommended for metronidazole 2gm.
Vulvovaginal Candidiasis: Fluconazole 150mg provides single-dose antifungal therapy for uncomplicated VVC.
Mixed Infections: Multiple studies confirm that BV, VVC, and STIs frequently co-exist. VAGIMIST KIT treats all simultaneously, reducing the risk of incomplete treatment of one condition while treating another.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
Vaginal discharge is the most common gynaecological complaint in Indian outpatient practice, and mixed infections are the rule rather than the exception — studies consistently show that 20–30% of women presenting with vaginal discharge have concurrent BV and VVC, and a significant proportion have coexisting STIs. Treating each infection separately with multiple prescriptions leads to poor compliance — many women take treatment for one condition and not the other, leading to persistent symptoms and antibiotic resistance.
VAGIMIST KIT solves this clinically and practically by providing a single-dispensing, single-visit complete treatment. For gynaecologists and general physicians in high-STI-prevalence settings, the convenience and compliance advantage of a kit approach is substantial. The secnidazole single-dose BV treatment is a particular differentiator — the evidence for single-dose secnidazole achieving equivalent BV cure rates to 7-day metronidazole while dramatically improving compliance is well-established.
At ₹1450, VAGIMIST KIT is priced at a premium appropriate for a specialist gynaecology product while remaining accessible to the patient population it serves. For franchise partners, STI treatment kits are a high-value, consistent-demand segment in gynaecology-heavy market territories.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.